Torigen Expands Histopathology Services Through Strategic Partnership with Vidium Animal Health

Comprehensive specialty services will lead to more accurate diagnoses in companion animals

FARMINGTON, CONN. (PRWEB) APRIL 27, 2022

Torigen Pharmaceuticals, Inc, a commercial-stage animal health biologics company, today announced it has entered into a strategic partnership with Vidium Animal Health® to offer veterinarians a full spectrum of services from diagnosis to treatment. Vidium Animal Health combines extensive expertise in veterinary cancer pathology with genomic diagnostic testing to bring unparalleled advanced cancer diagnostics to veterinary medicine.

This strategic partnership enhances Torigen’s ability to provide advanced cancer care solutions for companion animals. Torigen offers an experimental autologous cancer immunotherapy that is created from a surgically resected portion of tumor tissue. A definitive cancer diagnosis is necessary for Torigen to create the individualized therapy. The combination of Vidium’s industry leading oncopathologists with Torigen’s expert veterinary oncologists provides veterinarians with a precise diagnosis and an innovative cancer treatment plan.

Read the full news release here>>